Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.55 |
| ▸ | AVPR2 | P30518 | 4/20 | 0.53 |
| ▸ | AVPR1A | P37288 | 4/20 | 0.53 |
| ▸ | OXTR | P30559 | 1/20 | 0.53 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4129674 | 0.86 | TSHR (0.61) | SMN1; SMN2ALDH1A1TSHRMAPTKMT2A | |
| SCHEMBL1800914 | 0.85 | SMN1; SMN2 (0.58) | RAB9ASMN1; SMN2ALDH1A1TSHRP2RY1 | |
| SCHEMBL842376 | 0.85 | AVPR2 (0.54) | RAB9ASMN1; SMN2ALDH1A1AVPR2AVPR1A | |
| SCHEMBL6418776 | 0.84 | PDE4A (0.61) | ALDH1A1AVPR2AVPR1AOXTRKDM4E | |
| SCHEMBL4131021 | 0.81 | P2RY1 (0.66) | RAB9ASMN1; SMN2ALDH1A1TSHRP2RY1 | |
| SCHEMBL1171653 | 0.80 | KMT2A (0.57) | RAB9ASMN1; SMN2ALDH1A1TSHRKDM4E | |
| SCHEMBL1171649 | 0.80 | KMT2A (0.57) | RAB9ASMN1; SMN2ALDH1A1TSHRKDM4E | |
| SCHEMBL11091013 | 0.80 | KMT2A (0.57) | RAB9ASMN1; SMN2ALDH1A1TSHRKDM4E | |
| SCHEMBL24157994 | 0.76 | RAB9A (1.00) | RAB9ASMN1; SMN2ALDH1A1TSHRMEN1 | |
| SCHEMBL12617577 | 0.76 | MGLL (0.45) | RAB9ASMN1; SMN2ALDH1A1TSHRP2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-7504508-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7211672-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| EP-1740547-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20060106061-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2006-05-18 | — | — | US | disclosed |
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2005-11-17 | — | — | US | disclosed |
| WO-2005100321-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| EP-1556047-A2 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-07-27 | — | — | EP | disclosed |
| US-20040082609-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2004032848-A2 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | RAB9A 2883/4885SMN1; SMN2 4770/4885ALDH1A1 1599/4885 |
| US-20060106061-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | RAB9A 2765/4885SMN1; SMN2 4803/4885ALDH1A1 2039/4885 |
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | RAB9A 2883/4885SMN1; SMN2 4770/4885ALDH1A1 1599/4885 |
| US-20040082609-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, PTGDR, LTB4R2 | RAB9A 3346/4885SMN1; SMN2 4763/4885ALDH1A1 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.